ArticleDiabetes, obesity & metabolism2020

Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials.

Subodh Verma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.